CoMeD Urges to Make Pharmaceuticals Mercury-free

The Coalition for Mercury-free Drugs (CoMeD) had a meeting with officials from the United States Department of State to discuss the inclusion of pharmaceuticals in the upcoming treaty negotiations about a global treaty on mercury.

Scientists and advocates from the Coalition for Mercury-free Drugs (CoMeD) had a meeting Thursday with officials from the United States (U.S.) Department of State and other government agencies to discuss the inclusion of pharmaceuticals in the upcoming treaty negotiations in Nairobi, Kenya about a global treaty on mercury being developed by the United Nations Environment Programme (UNEP). 

CoMeD, and the international coalition it leads, provided a compendium of the latest evidence for the serious danger represented by the on-going use of mercury in medicine, especially Thimerosal (49.6% mercury by weight) in vaccines as well as the continuing use of mercury-silver-amalgam fillings in dentistry. CoMeD explained the feasibility of using 2-phenoxyethanol, a much less toxic, non-bioaccumulative, cost-effective alternative to Thimerosal.